Knowledge Library

Antibody Discovery Platform

WuXi AppTec provides integrated and cost-effective services for: Polyclonal and monoclonal antibodies Anti-drug antibodies (ADA), host cell protein (HCP) antibodies, surrogate antibodies, diagnostic antibodies, therapeutic antibodies Antibody drug conjugate services, including site-specific conjugation Related antibody services, including peptide design and recombinant protein production

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Immunology, Oncology

VIEW

OncoWuXi Express: Review of SITC 2023 Annual Meeting

Review of SITC 2023 Annual Meeting The 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) was held this year in San Diego, CA, USA. As one of the most influential international conferences dedicated to cancer immunotherapy, SITC provides attendees with a cross-disciplinary educational and interactive platform. This meeting focuses on discussing and …Read More >

Resource Type: Article, Blog
Resource Topic: Antibodies, Autoimmune and Inflammatory Diseases, Cell-based Assays, in vivo Pharmacology, Oligonucleotides, Oncology

VIEW

Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibodies, Cell-based Assays, Oligonucleotides, Oncology, Tumor Models

VIEW

Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment

SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by upregulating PD-L1 expression. Consequently, combining KRAS G12C inhibitors with immune checkpoint blockers shows promising benefits. To better understand the mechanisms underlying the combined inhibition of KRAS G12C inhibitor AMG 510, and anti-PD-1 antibody nivolumab, LU-01-0361 …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibodies, Oncology, Small Molecules, Tumor Models

VIEW

OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)

Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages such as a wide target range, programmability, and rapid iteration.  However, the wide application of nucleic acid drugs still faces many challenges, including delivery efficiency and off-target effects. To address these challenges, the Oncology-Immunology team …Read More >

Resource Type: Article, Blog, Case Study
Resource Topic: Antibodies, Cell-based Assays, Oncology, Tumor Models

VIEW

WuXi AppTec in vitro Neuroscience Services

Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However, due to poor disease and target understanding, Neuroscience drug discovery can be very challenging. An open access research platform with dedicated neuroscience specialists and integrated services will be an ideal partner throughout your drug discovery …Read More >

Resource Type: Brochure
Resource Topic: Antibodies, Biochemical Assays, Biomarkers, Cell-based Assays, Cells and Protein Science, Central Nervous System & Pain, Hit Finding, Hit-to-Lead, in vitro biology, Lead Optimization, Phenotypic Assays, Rare Diseases, Safety and Early Toxicity, Small Molecules, Target Identification and Validation

VIEW

OncoWuXi Newsletter November 2022

Resource Type: Newsletter
Resource Topic: Antibodies, Antibody Drug Conjugate, Autoimmune and Inflammatory Diseases, Biomarkers, Cell-based Assays, Cells and Protein Science, Hit-to-Lead, Lead Optimization, Oncology

VIEW

How Does It Work? | Peptibodies

#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by fusing #therapeutic peptides to the Fc region of an antibody to create what is known as a peptibody. When the peptibody is naturally taken up by cells it binds to an Fc (antibody) receptor within …Read More >

Resource Type: Video
Resource Topic: Antibodies, Cells and Protein Science, Oncology, Target-Specific Assays

VIEW

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Antibodies, Biomarkers, CAR-T Cell, Cell Therapies, Cell-based Assays, Cells and Protein Science, Oncology, Target Identification and Validation

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!